Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834789 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT06834789 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 132 participants.
The verdict
NCT06834789, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).
Interventions
- DRUG Placebo
- DRUG OnabotulinumtoxinA
- DRUG AGN-151586
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2025-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06834789
The ClinicalTrials.gov registry entry for NCT06834789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06834789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06834789 about?
NCT06834789 is a clinical study titled "A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)". The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).
What is the current status of trial NCT06834789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-02-18. Estimated completion is 2025-11-03.
What interventions are being tested in trial NCT06834789?
The interventions under investigation include: Placebo (DRUG), OnabotulinumtoxinA (DRUG), AGN-151586 (DRUG).
Who is sponsoring clinical trial NCT06834789?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.